The Food and Drug Administration (FDA) has detailed stringent policies for the approval of diabetic drugs. These policies compel lengthier clinical trials, often resulting in the delayed launch of new drugs and increased drug development costs. "The not-so conducive regulatory environment, varying price controls across countries and parallel trading hinders the growth of the global diabetes market," adds the analyst. "In addition, generic competition arising due to patent expiries of major drugs is also restraining market expansion."

Despite these obstacles, the diabetes market is, and will continue to be, a lucrative segment of the healthcare industry. Numerous innovative drugs and drug-delivery devices are currently being researched. Given these are successful; the launch of such drugs and devices will further open up the market and boost revenue generation. "Asian markets, especially India and China, offer tremendous prospects for growth," concludes the analyst. "These markets have large diabetic populations and, with the number of undiagnosed diabetics increasing, lucrative untapped opportunities are emerging for pharmaceutical companies."

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

Insulin Insulin analogues Non-insulin anti-diabetic drugs

By Geographic Region:

The U.S. Europe Japan Rest-of-World

researchandmarkets/